Emergent BioSolutions, Inc. will ask a US Food and Drug Administration advisory panel to agree that rearranging the placement of directions within labeling it tested for OTC use of its naloxone nasal spray will eliminate user errors which concern agency officials.
FDA officials, however, will explain at a joint meeting of the Nonprescription Drug and Anesthetic and Analgesic Drug Products advisory...